Progen gets strategic advice
Wednesday, 27 August, 2008
Progen Pharmaceuticals [ASX: PGL] has appointed a new group of corporate advisors to help guide the company's development.
The company has commissioned the services of the independent corporate advisory firm Beerworth and Partners (BPL).
BPL has been hired to assess Progen's operations and develop strategic options to be reviewed by Progen's Board of directors.
The advisory firm will also provide general corporate advice and assist the board as required.
According to Progen, the decision to hire advisors was made when the directors realised the company's strong cash position after terminating the PI88 Phase III Pathway study in liver cancer.
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
Newborns have elevated levels of an Alzheimer's biomarker
What do the brains of newborns and patients with Alzheimer's disease have in common? Both...
